Insider · CIK 0001664281
Kush Parmar
Files at SKYE (Skye Bioscience, Inc.), TRDA (Entrada Therapeutics, Inc.), CAMP (Camp4 Therapeutics Corp), LTGO (Latigo Biotherapeutics, Inc.). First filing Jul 1, 2025, latest Nov 18, 2025.
Kush Parmar files SEC Form 4 as 10% owner and director at TRDA (Entrada Therapeutics, Inc.), and also at SKYE (Skye Bioscience, Inc.), CAMP (Camp4 Therapeutics Corp), LTGO (Latigo Biotherapeutics, Inc.). Since Jul 1, 2025, Kush Parmar has reported 0 open-market buys worth $0 and 3 open-market sells worth $2.8M, the latest filed on Nov 18, 2025.
A track record needs three past buys with six months of prices behind them; Kush Parmar has 0, so none is measured yet.
The newest scored trade: sold $1.8M of TRDA on Nov 14, 2025, filed Nov 18, 2025, scored 55 (moderate). In the last 12 months: 0 buys worth $0 and 1 sell worth $1.8M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TRDA: Entrada Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 55Moderate | Entrada Therapeutics, Inc. | $1.8M 200,000 shares | -6% | +74% from low-59% from high | |
| 35Weak | Entrada Therapeutics, Inc. | $203k 27,000 shares | -1% | +13% from low-65% from high | |
| 46Moderate | Entrada Therapeutics, Inc. | $867k 125,000 shares | -4% | 0% from low-68% from high |
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | TRDA Entrada Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 12, 2026 |
| Nov 14, 2025 | TRDA Entrada Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By 5AM Ventures V, L.P. | -200,000 | $8.80 | $1.8M | 2,963,066 | Nov 18, 2025 |
| Jul 9, 2025 | TRDA Entrada Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By 5AM Ventures V, L.P. | -20,065 | $7.50 | $151k | 3,163,066 | Jul 11, 2025 |
| Jul 9, 2025 | TRDA Entrada Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By 5AM Opportunities I, L.P. | -6,935 | $7.50 | $52k | 1,093,313 | Jul 11, 2025 |
| Jun 27, 2025 | TRDA Entrada Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By 5AM Ventures V, L.P. | -55,735 | $6.91 | $385k | 3,220,287 | Jul 1, 2025 |
| Jun 27, 2025 | TRDA Entrada Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By 5AM Opportunities I, L.P. | -19,265 | $6.91 | $133k | 1,113,092 | Jul 1, 2025 |
| Jun 30, 2025 | TRDA Entrada Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By 5AM Ventures V, L.P. | -18,578 | $6.81 | $127k | 3,201,709 | Jul 1, 2025 |
| Jun 30, 2025 | TRDA Entrada Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By 5AM Opportunities I, L.P. | -6,422 | $6.81 | $44k | 1,106,670 | Jul 1, 2025 |
| Jul 1, 2025 | TRDA Entrada Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By 5AM Ventures V, L.P. | -18,578 | $7.12 | $132k | 3,183,131 | Jul 1, 2025 |
| Jul 1, 2025 | TRDA Entrada Therapeutics, Inc. | SOpen-market sale Common Stockindirect: By 5AM Opportunities I, L.P. | -6,422 | $7.12 | $46k | 1,100,248 | Jul 1, 2025 |
| Jun 11, 2025 | TRDA Entrada Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +19,000 | $0.00 | $0 | 19,000 | Jun 12, 2025 |
Questions about Kush Parmar
Answered from the filings on this page, as of the latest one.
Is Kush Parmar buying or selling?
In the last 12 months Kush Parmar reported 0 open-market buys worth $0 and 1 open-market sell worth $1.8M on SEC Form 4; the latest was sold $1.8M of TRDA on Nov 14, 2025. Grants, option exercises and tax withholding are not counted.
How did Kush Parmar's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kush Parmar has 0.
Where does Kush Parmar file Form 4?
Kush Parmar has filed Form 4 at TRDA (Entrada Therapeutics, Inc.); SKYE (Skye Bioscience, Inc.); CAMP (Camp4 Therapeutics Corp); LTGO (Latigo Biotherapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.